Browse Studies — Arctuva

Phase 1

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

To evaluate safety and determine the recommended Phase II dose (RP2D). We hypothesize that targeting leukemia stem/progenitor cells (LSCs) with nadunolimab (IL…

Myelodysplastic Syndrome(MDS)Acute Myelogenous Leukemia (AML)

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06548230

Phase 2

Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults

Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transpl…

Acute Myelogenous Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)Chronic Myelogenous Leukemia (CML)+3 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT05884333

Phase 2

A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related…

Fanconi AnemiaSevere Marrow FailureMyelodysplastic Syndrome (MDS)+1 more

Estimated

~$10 – $5,625

Children's Hospital Medical Center, CincinnatiNCT02143830